Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

June 5, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • FEATURED
  • Recent studies show certain Microbiota treatments are backfiring!

Genetic reprogramming - the cellular machinery of yeast to create factories that convert sugars and amino acids into plant-based drugs

JNU | JRF position |DBT funded Project

Recent studies show certain Microbiota treatments are backfiring!
  • BiotechToday
  • FEATURED
  • World

Recent studies show certain Microbiota treatments are backfiring!

bioxone September 7, 2020September 7, 2020

–Raddur Samaddar, Amity University Kolkata

Hypoxia is the talk of the town now, especially with the advent of COVID-19, curing of patients with severe levels of infection, escalating to respiratory problems, with oxygen-induced treatment is a major form of supportive care. Scientists have come up with a study that provides information on gut microbiota and their contribution to severe Hypoxia.

Up till now, we were confident about the fact that oxygen is the most important treatment ‘drug’ and any drug of choice has to be used in the correct dosage for treatment. The study has been performed with all the important parameters such as Comparative study with Human and Mice models, the dysbiosis in lungs, the correlations among hypoxia, the cecal microbiota composition, and alveolar inflammation with the antibiotic treatment and its effects. In untreated mice, treatment with excessive amounts of oxygen leads to a change in the mice’s microbiota, and a rise in the population of the Staphylococcus species was noted. It was inferred that such population alterations of the microbes were precursive to the onset of inflammation.

The aim of the study is to show how Hypoxia alters the microbiota growth conditions and also how a microbe-free environment is actually helping in the treatment. The harm we knew we were causing will be now proved from a therapeutic standpoint and we can alter the microbiota accordingly. Successive experiments would find out how such microbial manipulations would work.

Source: Lung and gut microbiota are altered by hyperoxia and contribute to oxygen-induced lung injury in mice. Ashley, S. L., Sjoding, M. W., Popova, A. P., Cui, T. X., Hoostal, M. J., Schmidt, T. M., Branton, W. R., Dieterle, M. G., Falkowski, N. R., Baker, J. M., Hinkle, K. J., Konopka, K. E., Erb-Downward, J. R., Huffnagle, G. B., & Dickson, R. P. (2020). Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aau9959,

https://stm.sciencemag.org/content/12/556/eaau9959/tab-pdf

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Covid Hypoxia Microbiota

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

JNU | JRF position |DBT funded Project

bioxone September 7, 2020

–Shristi Sharma, Amity University Kolkata Applications are invited for ONE Junior Research Fellow in the DBT funded project entitled “Study of in-depth genetic heterogeneity with respect to resistome and compensatory adaption of MDR Mtb clinical strains inside BM-Mesenchymal stem cells circulating in the North-East Region” in the laboratory of the undersigned. Salary: Rs.31,000/- per month + 24% HRA Essential Qualification: Post […]

Related Post

  • BiotechToday
  • World

WILL COVID-19 VACCINE WORK?

bioxone October 31, 2020October 30, 2020

Chitra Roy, University of Calcutta As we are getting closer to the COVID-19 vaccine, it is exciting to think of the day when the virus will be gone. But, the COVID-19 vaccine will not be the magic bullet considering its efficacy and the challenges currently being faced in these efficacy studies. Efficacy of a vaccine […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Olfactory senses in the red flour beetle as a behavioral inducer!

BioTech Today August 1, 2021July 31, 2021

Saptaparna Dasgupta, Bennett University Insects are highly dependent on their olfactory senses for the translation of the happenings in their environment. In the red flour beetle Tribolium castaneum, during metamorphosis, the neural system generally experiences significant change. The integration of new neurons, and the modification and removal of larval neurons, are all part of this […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

A relaxin based nanoparticle treats liver fibrosis

bioxone January 29, 2021January 29, 2021

PRIYANKA CHAKRABORTY, AMITY UNIVERSITY, KOLKATA Liver fibrosis is one of the leading causes of morbidity and mortality among human beings. The unavailability of proper antifibrotic therapy makes the disease more deadly and the patients more vulnerable. RLX ( peptide hormone human relaxin-2), acting through a G protein-coupled receptor relaxin peptide receptor 1 (RXFP1), promotes tissue […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy